Zolmitriptan: a new acute treatment for migraine

Area of Science:

• Pharmacology
• Neurology
• Clinical Therapeutics

Background:

• Migraine treatment requires effective acute therapies with improved pharmacokinetic profiles.
• Selective serotonin 5-HT(1B/1D) receptor agonists represent a key therapeutic class.
• Zolmitriptan was developed to enhance oral bioavailability and central nervous system (CNS) penetration compared to earlier agents.

Purpose of the Study:

• To evaluate the efficacy and tolerability of zolmitriptan as an oral acute treatment for migraine.
• To assess the pharmacokinetic properties of zolmitriptan following oral administration.
• To compare the central action of zolmitriptan with sumatriptan in migraineurs.

Main Methods:

• Pharmacokinetic analysis of oral zolmitriptan absorption, bioavailability, and elimination half-life.
• Clinical trials assessing 2-hour headache response rates at various zolmitriptan doses.
• Electrophysiological studies in migraineurs to investigate central nervous system effects.
• Long-term treatment monitoring for efficacy, tolerability, and quality of life impact.

Main Results:

• Zolmitriptan demonstrated rapid oral absorption, reaching C(max) within 1 hour, with approximately 40% bioavailability.
• A consistent 2-hour headache response rate of 60-70% was observed at doses of 2.5 mg and higher.
• Long-term treatment showed high response rates (>80%) and improved quality of life, with a safety profile similar to other 5-HT(1B/1D) agonists.

Conclusions:

• Zolmitriptan is a well-tolerated and effective oral medication for acute migraine treatment.
• Its pharmacokinetic profile and demonstrated central action support its suitability as a first-line therapy.
• Zolmitriptan offers significant benefits, including improved quality of life, for individuals experiencing migraines.